Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - Results of the eLEcTRA trial

被引：168

作者：

Huober, J. ^{[1
,5
]}

Fasching, P. A. ^{[2
,14
]}

Barsoum, M. ^{[3
]}

Petruzelka, L. ^{[4
]}

Wallwiener, D. ^{[5
]}

Thomssen, C. ^{[6
]}

Reimer, T. ^{[7
]}

Paepke, S. ^{[8
]}

Azim, H. A. ^{[9
]}

Ragosch, V. ^{[10
]}

Kubista, E. ^{[11
]}

Baumgaertner, A. K. ^{[8
]}

Beckmann, M. W. ^{[2
]}

May, C. ^{[12
]}

Nimmrich, I. ^{[12
]}

Harbeck, N. ^{[8
,13
]}

机构：

[1] Kantonsspital, Breast Ctr, CH-9007 St Gallen, Switzerland

[2] Univ Erlangen Nurnberg, Dept Gynaecol, D-91054 Erlangen, Germany

[3] Cairo Univ, Natl Canc Inst, Cairo, Egypt

[4] Univ Hosp Prague, Dept Oncol, Prague, Czech Republic

[5] Univ Tubingen, Dept Obstet & Gynaecol, Tubingen, Germany

[6] Univ Halle Wittenberg, Dept Gynaecol, Halle, Saale, Germany

[7] Univ Rostock, Dept Obstet & Gynaecol, Rostock, Germany

[8] Tech Univ Munich, Frauenklin Rechts Isar, Munich, Germany

[9] Cairo Univ, Fac Med, Dept Clin Oncol, Cairo, Egypt

[10] Asklepios Klin Altona, Dept Gynaecol, Hamburg, Germany

[11] Med Univ Vienna, Dept Gynaecol, Vienna, Austria

[12] Novartis Pharrna GmbH BU Oncol, Nurnberg, Germany

[13] Univ Cologne, Breast Ctr, Dept OB&GYN, D-50931 Cologne, Germany

[14] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Hematol & Oncol, Los Angeles, CA 90095 USA

来源：

BREAST | 2012年 / 21卷 / 01期

关键词：

Metastatic breast cancer; Endocrine treatment; Letrozole; Trastuzumab; ADJUVANT CHEMOTHERAPY; ESTROGEN-RECEPTOR; ENDOCRINE THERAPY; TAMOXIFEN; HER-2/NEU; ARIMIDEX; SAFETY; PLUS; HER2;

D O I：

10.1016/j.breast.2011.07.006

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The eLEcTRA trial compared efficacy and safety of letrozole combined with trastuzumab to letrozole alone in patients with HER2 and hormone receptor (HR) positive metastatic breast cancer (MBC). Patients were randomized to either letrozole alone (arm A, n = 31) or letrozole plus trastuzumab (arm B, n = 26) as first-line treatment. Additional 35 patients with HER2 negative and HR positive tumors received letrozole alone (arm C). Median time to progression in arm A was 3.3 months compared to 14.1 months in arm B (hazard ratio 0.67; p = 0.23) and 15.2 months in arm C (hazard ratio 0.71; p = 0.03). Clinical benefit rate was 39% for arm A compared to 65% in arm B (odds ratio 2.99, 95% CI 1.01-8.84) and 77% in arm C (odds ratio 5.34, 95% CI 1.83-15.58). The eLEcTRA trial showed that the combination of letrozole and trastuzumab is a safe and effective treatment option for patients with HER2 positive and HR positive MBC. (C) 2011 Elsevier Ltd. All rights reserved.

引用

页码：27 / 33

页数：7

共 50 条

[21] Real-World Evidence of Trastuzumab, Pertuzumab, and Docetaxel Combination as a First-Line Treatment for Korean Patients with HER2-Positive Metastatic Breast Cancer
Lee, Yong-Pyo
Lee, Min-Sang
Kim, HongSik
Kim, Ji-Yeon
Ahn, Jin Seok
Im, Young-Hyuck
Park, Yeon Hee
CANCER RESEARCH AND TREATMENT, 2022, 54 (04): : 1130 - 1137
[22] Hormone-receptor expression and activity of trastuzumab with chemotherapy in HER2-positive advanced breast cancer patients
Montemurro, Filippo
Rossi, Valentina
Rocca, Maria Cossu
Martinello, Rossella
Verri, Elena
Redana, Stefania
Adamoli, Laura
Valabrega, Giorgio
Sapino, Anna
Aglietta, Massimo
Viale, Giuseppe
Goldhirsch, Aron
Nole, Franco
CANCER, 2012, 118 (01) : 17 - 26
[23] Complete response to pyrotinib combined with letrozole as first-line treatment of HER2-positive/HR-positive breast cancer: a case report
Xie, Ning
Liu, Liping
Tian, Can
Hu, Zheyu
Ouyang, Quchang
ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (16)
[24] Combination of metronomic capecitabine and letrozole in metastatic hormone receptor positive, HER2 negative breast cancer: a randomized phase II trial
Azim, Hamdy A.
Saleh, Mariam A.
Eldin, Passant Essam
Abdelhafeez, Ahmed A. M.
Hassan, Mohamed
Kassem, Loay
JOURNAL OF CHEMOTHERAPY, 2025, 37 (02) : 159 - 167
[25] Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancer
Onder Tonyali
Mustafa Benekli
Veli Berk
Ugur Coskun
Metin Ozkan
Ramazan Yildiz
Emel Ucgul
Alper Sevinc
Dogan Uncu
Umut Demirci
Suleyman Buyukberber
Journal of Cancer Research and Clinical Oncology, 2013, 139 : 981 - 986
[26] A Phase II Trial of Oxaliplatin and Trastuzumab in the Treatment of HER2-Positive Metastatic Breast Cancer
Yardley, Denise A.
Daniel, Davey
Stipanov, Michael
Drosick, D. Randolph
Mainwaring, Mark
Peyton, James
Shastry, Mythili
Hainsworth, John D.
CANCER INVESTIGATION, 2010, 28 (08) : 865 - 871
[27] Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer
Farhat, Fadi
Kattan, Joseph G.
Ghosn, Marwan
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 77 (05) : 1069 - 1077
[28] Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer
Fadi Farhat
Joseph G. Kattan
Marwan Ghosn
Cancer Chemotherapy and Pharmacology, 2016, 77 : 1069 - 1077
[29] Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results
Perez, Edith A.
Manuel Lopez-Vega, Jose
Petit, Thierry
Zamagni, Claudio
Easton, Valerie
Kamber, Julia
Restuccia, Eleonora
Andersson, Michael
BREAST CANCER RESEARCH, 2016, 18
[30] Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results
Edith A. Perez
José Manuel López-Vega
Thierry Petit
Claudio Zamagni
Valerie Easton
Julia Kamber
Eleonora Restuccia
Michael Andersson
Breast Cancer Research, 18

← 1 2 3 4 5 →